quizartinib
daiichi sankyo
['quizartinib', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'myeloid', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'daiichisankyous', 'daiichi']
three years after ' quizartinib was rejected by the fda for relapsed flt3+ acute myeloid leukaemia (#aml), the japanese #pharma is trying again in the first-line setting, with strong survival data reported at #eha2022 
https://t.co/O0ZJQGMjEP, and its digital magazine Deep Dive, is a leading online destination for healthcare and pharmaceutical industry news, insight and debate